Report cover image

Fresenius Kabi USA, LLC - Strategic SWOT Spotlight

Publisher Quaintel Research
Published Sep 04, 2024
Length 47 Pages
SKU # QTELR19136183

Description

Fresenius Kabi USA, LLC - Strategic SWOT Spotlight


Fresenius Kabi USA, LLC - Strategic SWOT Spotlight is a comprehensive and easily accessible overview of The Fresenius Kabi USA, LLC's business operations. It provides a Snapshot of the company's position in the industry compared to competitors. The report includs key executives, products and services, ESG spotlight, Corporate Strategy, Business Description, Helicopter view of SWOT Analysis, Competitive Landscape and latest events.

Key Highlights

Fresenius Kabi USA, LLC is a leading healthcare company that specializes in providing a wide range of products and services to improve patient care. They offer a variety of pharmaceuticals, medical devices, and clinical nutrition products that are used in hospitals, clinics, and other healthcare facilities. Their pharmaceutical products include injectable drugs, anesthesia, and critical care medications. They also offer medical devices such as infusion pumps, blood collection systems, and transfusion technology. In addition, Fresenius Kabi USA, LLC provides clinical nutrition products for patients who are unable to consume food orally. These offerings are designed to meet the needs of healthcare professionals and patients, with a focus on safety, quality, and innovation. Founded in 1912, the company is headquartered in Lake Zurich, IL, USA.

Fresenius Kabi USA, LLC in the News:-
  • 15-Apr-2024 - Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne, its Third Approved Biosimilar in the U.S.
  • 07-Mar-2024 - Fresenius Kabi's Biosimilar Tyenne (tocilizumab-aazg) becomes the first IV and Subcutaneous tocilizumab biosimilar approved by the FDA
  • 28-Feb-2024 - Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP
  • 29-Jan-2024 - Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections
  • 14-Dec-2023 - Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix Infusion System
Scope

Company Fundamentals:- These fundamentals offer valuable insights into Fresenius Kabi USA, LLC's operations, geographical presence, products and services, ESG spotlight, Corporate Strategy, Business Description and SWOT spotlight, aiding in a comprehensive understanding of the organization.

Reasons to Buy
  • Helicopter view of company's internal and external factors through SWOT analysis - Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers. - Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations. - Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Table of Contents

47 Pages
Table of Contents
Tables
Charts
Fresenius Kabi USA, LLC - Key Company Facts
Fresenius Kabi USA, LLC - Company Description
Fresenius Kabi USA, LLC - Top Executives
Fresenius Kabi USA, LLC - Head Office & Locations
Head Office - Country
Fresenius Kabi USA, LLC - Products and Services
Products
Services
Fresenius Kabi USA, LLC - Corporate Strategy
Fresenius Kabi USA, LLC - Business Description
Infusion Therapy Products and Services
Renal Care Products
Clinical Nutrition
Fresenius Kabi USA, LLC - ESG Spotlight
Environment
Social
Corporate Governance
Fresenius Kabi USA, LLC - SWOT Spotlight
Overview
Strengths
Weaknesses
Opportunities
Threats
Competing Players
Snapshot of Competing Players
Amphastar Pharmaceuticals Inc.
Key Financials:
Baxter International Inc.
Key Company Facts
Company Description
Key Financials:
Pfizer Inc.
Key Company Facts
Company Description
Key Financials:
Terumo Corporation
Key Company Facts
Company Description
Key Financials:
Galenica AG
Key Company Facts
Company Description
Key Financials:
Fresenius Kabi USA, LLC - In the News
15-Apr-2024- Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne, its Third Approved Biosimilar in the U.S.
07-Mar-2024- Fresenius Kabi's Biosimilar Tyenne (tocilizumab-aazg) becomes the first IV and Subcutaneous tocilizumab biosimilar approved by the FDA
28-Feb-2024- Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP
29-Jan-2024- Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections
14-Dec-2023- Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix Infusion System
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Research Methodology
Disclaimer
Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us